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Abstract: Oncoviruses cause tremendous global cancer burden. For several DNA tumor viruses,
human genome integration is consistently associated with cancer development. However,
genomic features associated with tumor viral integration are poorly understood. We sought
to define genomic determinants for 1897 loci prone to hosting human papillomavirus (HPV),
hepatitis B virus (HBV) or Merkel cell polyomavirus (MCPyV). These were compared to HIV,
whose enzyme-mediated integration is well understood. A comprehensive catalog of integration
sites was constructed from the literature and experimentally-determined HPV integration sites.
Features were scored in eight categories (genes, expression, open chromatin, histone modifications,
methylation, protein binding, chromatin segmentation and repeats) and compared to random
loci. Random forest models determined loci classification and feature selection. HPV and HBV
integrants were not fragile site associated. MCPyV preferred integration near sensory perception
genes. Unique signatures of integration-associated predictive genomic features were detected.
Importantly, repeats, actively-transcribed regions and histone modifications were common tumor
viral integration signatures.
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1. Introduction
Integration into the human genome is central to transposon mutagenesis, gene therapy and
viral pathogenesis [1–4]. DNA tumor virus integration has been implicated as an early oncogenic
event. Viral infections are responsible for a significant portion of the global cancer burden, with
over 1.2 million new cancer cases attributable to hepatitis viruses and human papillomavirus (HPV)
in 2008 [5]. Integrated high-risk HPVs, principally HPV-16 and -18, are associated with anogenital
and head and neck cancers (HNCs) [6]. Hepatitis B virus (HBV) integrates in up to 90% of HBV+
hepatocellular carcinomas (HCCs) [7,8]. Merkel cell polyomavirus (MCPyV) integrates in 70%–80%
of Merkel cell carcinomas (MCCs), an aggressive neuroendocrine skin cancer [9,10]. Integration
may increase cancer risk beyond simple infection. Following integration, increased expression of
the HPV oncogenes E6 and E7 and expression of truncated forms of HBV HBx and MCPyV Tag
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with increased oncogenic potential have been detected [11–13]. In addition, viral integration can
deregulate nearby human oncogenes [14,15], create oncogenic fusion genes [16,17] and contribute to
genome instability [8,18]. One potential strategy for reducing cancer risk in infected or early-stage
disease patients may be targeted prevention of viral integration. However, initial steps will require
a better understanding of DNA tumor virus integration.
Numerous studies have been conducted to determine preferential sites of DNA tumor virus
integration, with differing conclusions. HPV and HBV integrations were previously detected
at common fragile sites (CFSs), prone to breakage [7,8,19–22]. HPV, HBV and HIV were
thought to integrate in transcriptionally-active regions with accessible chromatin [15,23,24] and
near proliferation and cancer genes, like c-Myc and hTERT [14,20,25–29]. Others proposed that
DNA tumor virus integration occurred randomly [30,31], and cells bearing integrations selectively
underwent clonal expansion and tumorigenesis, with consequent observed biases reflecting
highly-represented integrations detected in cell populations [10,17,32,33]. Unlike the DNA tumor
viruses, HIV encodes an enzyme to catalyze integration [34].
Large-scale analyses of integration site selection have been conducted for transposons, gene
therapy vectors and HIV [1–4]. Previous analyses of tumor viral integration site preference focused
on integration in CFSs or near cancer/cell growth genes [8,27,32]. However, this large-scale study
is the first to compare genomic regions hosting the DNA tumor viruses HPV, HBV and MCPyV. We
hypothesized that host genome properties influence tumor viral integration. We found an overall bias
for integration near open chromatin regions and SINE elements for all DNA tumor viruses studied,
with differences between integration sites from different virus types, cancer types and disease stages.
2. Results
2.1. Catalog of Viral Integration Sites
HPV, HBV, MCPyV and HIV integrations with mapped genomic positions were cataloged
from the literature (references in File S1). A total of 589 HPV integration events from 436 cervical
carcinomas (CESCs) and 59 HNCs were cataloged. Remaining integrations were from other
carcinomas or cell lines. Several HPV types were represented, mostly HPV-16 (382) and HPV-18 (138)
(Table S1, Figure S1). Some analyses below were done for the entire set of HPV integration events
(n = 589) and for only those with precisely-mapped locations (n = 92). Viral integration site lengths
are provided (Figure S2). HBV integration sites (1271) included HCCs (628), tumor-adjacent samples
(600), both HCC and adjacent normal tissues (10) and cell lines (15) (Table S2). Thirty-seven MCPyV
integration sites were identified in MCCs (34), lung cancers (two) and a cell line (one) (Table S3). HIV
integration sites (45,304) were determined by Wang et al. by pyrosequencing [24]. Viral integration
sites are shown (Figure 1), and details and references are provided (File S1, Table S4).
2.2. Viral Integration Hotspots
Using the z-threshold method of Presson et al. [35] at a 99.5 percentile threshold, multiple
previously-described hotspots of HPV integration, including 8q24.11, 8q24.21 and 13q22.1,
were detected [14,20,26,36]. Using our expanded catalog, 15q22.1 and 17q23.1 [19,33], which
hosted multiple integration events in individual studies, were hotspots. HBV hotspots were
confirmed at 5p15.33, 19q13.12, 19q13.13 (99.5 percentile threshold) and 19q12 (99 percentile
threshold) [15,25,32,37] (Tables S5 and S6 and Figures S3 and S4). Interestingly, HIV had three
hotspots, at 16q24.3, 11q13.1 and 6p21.33 (Table S5 and Figure S3). Additional sites are needed to
assess recurrent MCPyV integration.
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Figure 1. Location of viral integration sites in the human genome. Human chromosomes (1–22, X, Y) 
are arranged around the circle. The inner-most ring shows viral integration sites, stacking multiple 
events that occurred at the same location. (a) HPV integration sites; (b) HBV integration sites;  
(c) MCPyV integration sites; (d) HIV integration sites. 
2.3. Evidence of Viral Integration Bias in Functional Genes 
Gene Ontology (GO) biological process terms were used to determine the integration preference 
near functional genes (Figure 2). Genes present within four window sizes (±100 bp, ±500 bp, ±1 kb 
and ±10 kb) around integration sites were assessed. For all windows, keratinocyte differentiation and 
keratinization terms were enriched among genes near HPV integrations. At ±10 kb, the zinc ion 
cellular response was enriched near HBV sites. G-protein-coupled receptor signaling and five terms 
associated with olfactory/sensory perception were significantly enriched for MCPyV in all windows. 
In agreement with a previous study [24], 196 terms related to cell cycle, mitosis, metabolism and 
transcription were enriched among genes within ±10 kb of HIV integrations (Figure 2). Significant 
GO biological process terms for the four viruses are provided (Table S6). 
Figure 1. Location of viral integration sites in the human genome. Human chromosomes (1–22,
X, Y) are arranged around the circle. The inner-most ring shows viral integration sites, stacking
multiple events that occurred at the same location. (a) HPV integration sites; (b) HBV integration
sites; (c) MCPyV integration sites; (d) HIV integration sites.
2.3. Evidence of Viral Integration Bias in Functional Genes
Gene Ontology (GO) biological process terms were used to determine the integration preference
near functional genes (Figure 2). Genes present within four window sizes (˘100 bp, ˘500 bp, ˘1 kb
and ˘10 kb) around integration sites were assessed. For all windows, keratinocyte differentiation
and keratinization terms were enriched among genes near HPV integrations. At ˘10 kb, the zinc ion
cellular response was enriched near HBV sites. G-protein-coupled receptor signaling and five terms
associated wi h olfactory/sensory perception were significantly e riched for MCPyV in all windows.
In agreement with a previous study [24], 196 terms relat to cell cycle, mitosis, metabolism and
transcription were enriched among genes within ˘10 kb of HIV integrations (Figure 2). Significant
GO biological process terms for the four viruses are provided (Table S7).
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Figure 2. GO biological process term enrichment of genes near viral integration sites. GO terms that 
were significant after the Fisher exact test with Bonferroni multiple testing correction (p < 0.05) are 
shown. For HIV, only the terms with the 20 lowest p-values are shown. 
2.4. No Evidence for Preferential Integration of DNA Tumor Viruses in CFSs 
Others have determined that CFSs are prone to HPV and HBV integration [7,8,19–22]. Using the 
binomial test, the frequency of viral integration in CFSs was compared to the fraction of the genome 
within CFSs. HPV, HBV and MCPyV integration rates in CFSs were not significantly different than 
expected (α = 0.05). However, HIV exhibited a small, but significant bias for integration in CFSs  
(p < 2.2 × 10−16) (Table S7). It is important to note that several integration hotspots coincide with CFSs, 
including HPV hotspots 8q24.1, 15q22 and 17q23.1, HBV hotspot 19q13 and HIV hotspot 11q13. 
However, when generalized to all integration sites, the frequency of integration in CFSs is not 
significantly different than expected by chance. 
2.5. Tumor Viral Integration Did Not Require Sequence Preference 
HIV and other integrase-dependent elements have preferred sequence motifs at their integration 
sites [1,38,39]. There are no known sequence motifs for HPV [40], HBV or MCPyV integration. 
Sequences ±10 bp from integration sites were examined for de novo motifs using HOMER, with 
randomly-selected sites as the background. Ten background (BG) sets with length-matched random 
loci for each viral integration site were selected. To control for gene density effects, ten additional 
random sets, gene constraint (GC) sets, were selected with a similar number of nearby genes (gene 
presence score). The HIV integration site motif 5′-GT(A/T)AC-3′ was recovered using both BG and 
GC sets. An additional motif, CGACTAGT, was identified using both random sets (Table S8). 
Figure 2. GO biological process term enrichment of genes near viral integration sites. GO terms that
were significant after the Fisher exact test with Bonferroni multiple testing correction (p < 0.05) are
shown. For HIV, only the terms with the 20 lowest p-values are shown.
2.4. No Evidence for Preferential Integration of DNA Tumor Viruses in CFSs
Others have determined that CFSs are prone to HPV and HBV integration [7,8,19–22]. Using
the binomial test, the frequency of viral integration in CFSs was compared to the fraction of the
genome within CFSs. HPV, HBV and MCPyV integration rates in CFSs were not significantly different
than expected (α = 0.05). However, HIV exhibited a small, but significant bias for integration in
CFSs (p < 2.2 ˆ 10´16) (Table S8). It is important to note that several integration hotspots coincide
with CFSs, including HPV hotspots 8q24.1, 15q22 and 17q23.1, HBV hotspot 19q13 and HIV hotspot
11q13. However, when generalized to all integration sites, the frequency of integration in CFSs is not
significantly different than expected by chance.
2.5. Tumor Viral Integration Did Not Require Sequence Preference
HIV a d other integrase-dependent lem nts have prefe red sequence motifs at their integration
sites [1,38,39]. There are no known sequence motifs for HPV [40], HBV or MCPyV integration.
Sequences ˘10 bp from integration sites were examined for de novo motifs using HOMER, with
randomly-selected sites as the background. Ten background (BG) sets with length-matched random
loci for each viral integration site were selected. To control for gene density effects, ten additional
random sets, gene constraint (GC) sets, were selected with a similar number of nearby genes (gene
presence score). The HIV integration site motif 51-GT(A/T)AC-31 was recovered using both BG
and GC sets. An additional motif, CGACTAGT, was identified using both random sets (Table S9).
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Significant motifs were not identified for HPV, HBV or MCPyV. The analysis was repeated using only
precisely-mapped HPV sites. Again, no significant motifs were identified.
2.6. Feature Scoring and Data Integration
For each integration site, 277 genomic features, including gene presence, gene expression, open
chromatin, histone modifications, DNA methylation, transcription factor (TF) and other protein
binding, chromatin segmentations and repeats, were scored within four windows of ˘100 bp,
˘500 bp, ˘1 kb and ˘10 kb (Figure 3, Table 1, data sources in Table S10). Because gene
expression, DNA-protein binding and epigenetic marks differ between cell types, cell lines were
chosen that represent the viral tropism and have ENCODE data available [41]. HPV and MCPyV
are epithelial-tropic, hence HPV-positive HeLa and SiHa cells and HPV-negative NHEK were used.
HepG2, a hepatocyte cell line, was used for liver-tropic HBV. GM12878, a T-lymphoblastoid cell line,
was used to study HIV integration [24].
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Figure 3. Genomic features near integration sites. (a) Categories of genomic features in the context of 
chromatin; (b) windows of four sizes are defined around viral integration sites, and features present 
in the human genome within each window are scored. Integration sites may be precisely mapped or 
be broader regions. 
2.7. Genomic Features Were Associated with Integration 
To investigate viral integrant distribution with respect to genomic features, the Wilcoxon rank 
sum test with Bonferroni correction was used. Significant differences between MCPyV integration 
and random sites were not detected among genomic features compared to BG or GC, likely owing to 
low sample size. For HPV and HBV, more genomic features were significantly different in cell lines 
relevant to viral tropism (HPV: HeLa-S3, NHEK, SiHa; HBV: HepG2; HIV: GM12878) (Figures S5 and 
S6). Genomic features that did not differ between cell lines (gene presence and repeats) and genomic 
features from cell lines most relevant to each virus were further analyzed (HPV: 98 genomic features; 
HBV: 95 genomic features; HIV: 120 genomic features) (Figure 4). Most genomic features that differed 
scored higher at viral integration sites than random sets. However, LINE elements were significantly 
underrepresented, and SINE elements were preferred, near viral integration sites for these three 
viruses. Transcriptionally-repressed regions (R segmentation) hosted fewer HPV and HIV 
integrations than random. Significantly higher scores for gene presence, euchromatin, transcribed 
region (T) segmentation and Pol2 binding indicated that all tumor viruses preferred integration in 
gene-dense, transcribed regions. HPV showed less preference for specific TF binding than HBV or 
HIV. Importantly, in this study, hypermethylation of H3K4 was detected in HeLa, HepG2 and NHEK 
cells near integration loci for these three viruses. Methylated H3K4 has been previously associated 
with the introduction of double-strand DNA breaks by recombination activating gene 1 (RAG1) and 
RAG2 complex in lymphocytes [42]. 
 
Figure 3. Genomic features near integration sites. (a) Categories of genomic features in the context of
chromatin; (b) windows of four sizes are defined around viral integration sites, and features present
in the human genome within each window are scored. Integration sites may be precisely mapped or
be broader regions.
2.7. Genomic Features Were Associated with Integration
To investigate viral integrant distribution with respect to genomic features, the Wilcoxon rank
sum test with Bonferroni correction was used. Significant differences between MCPyV integration
and random sites were not detected among genomic features compared to BG or GC, likely owing
to low sample size. For HPV and HBV, more genomic features were significantly different in
cell lines relevant to viral tropism (HPV: HeLa-S3, NHEK, SiHa; HBV: HepG2; HIV: GM12878)
(Figures S5 and S6). Genomic features that did not differ between cell lines (gene presence and
repeats) and genomic features from cell lines most relevant to each virus were further analyzed
(HPV: 98 genomic features; HBV: 95 genomic features; HIV: 120 genomic features) (Figure 4). Most
genomic features that differed scored higher at viral integration sites than random sets. However,
LINE elements were significantly underrepresented, and SINE elements were preferred, near viral
integration sites for these three viruses. Transcriptionally-repressed regions (R segmentation) hosted
fewer HPV and HIV integrations than random. Significantly higher scores for gene presence,
euchromatin, transcribed region (T) segmentation and Pol2 binding indicated that all three viruses
preferred integration in gene-dense, transcribed regions. HPV showed less preference for specific
TF binding than HBV or HIV. Importantly, in this study, hypermethylation of H3K4 was detected in
HeLa, HepG2 and NHEK cells near integration loci for these three viruses. Methylated H3K4 has
been previously associated with the introduction of double-strand DNA breaks by recombination
activating gene 1 (RAG1) and RAG2 complex in lymphocytes [42].
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Table 1. Summary of genomic features. All genomic feature scores were normalized for the length of the search region. * From ENCODE.







Data Type GENCODE, COSMICCancer Gene Census RNA-seq
DNase-seq,
FAIRE-seq ChIP-seq Methyl-RRBS ChIP-seq








HeLa *, NHEK *,
HepG2 *,
GM12878 *





HeLa *, NHEK *,
HepG2 *,
GM12878 *
HeLa *, HepG2 *,
GM12878 * hg19
Scoring Method Number of genes Sum of RPKM Number of peaks Number of peaks PercentMethylated Number of peaks Length of segment Length of repeat
Number of Features 2 5 8 44 3 178 21 16
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Figure 4. Significant differences were detected between viral integration sites and random sites.  
(a) HPV; (b) HBV; (c) HIV. Significance was determined using a two-sided Mann–Whitney U-test 
with Bonferroni correction, α < 0.05. Comparisons using the gene constraint set are indicated with 
GC. No significant differences were found for MCPyV. Only the features from the most relevant cell 
lines were considered for each virus. 
2.8. Genomic Features Predicted Integration 
Random forest (RF), a decision tree-based classification method, determined which genomic 
features were important for distinguishing actual DNA tumor virus integration sites from random 
sites. RFs were built using the 10 BG and GC sets. Genomic features associated with gene presence 
and repeats and cell lines most relevant to each virus were used (HPV: HeLa-S3, NHEK, SiHa  
(98 genomic features); HBV: HepG2 (95 genomic features); MCPyV: HeLa-S3, SiHa and NHEK  
(98 genomic features)). Recursive feature elimination selected the smallest subset of genomic features, 
resulting in an RF that performed nearly as well as the best model (Figure 5). 
Figure 4. Significant differences were detected between viral integration sites and random sites.
(a) HPV; (b) HBV; (c) HIV. Significance was determined using a two-sided Mann–Whitney U-test
with Bonferroni correction, α < 0.05. Comparisons using the gene constraint set are indicated with
GC. No significant differences were found for MCPyV. Only the features from the most relevant cell
lines were considered for each virus.
2.8. Genomic Features Predicted Integration
Random forest (RF), a decision tree-based classification method, determined which genomic
features were important for distinguishing actual DNA tumor virus integration sites from random
sites. RFs were built using the 10 BG and GC sets. Genomic features associated with gene presence
and repeats and cell lines most relevant to each virus were used (HPV: HeLa-S3, NHEK, SiHa
(98 genomic features); HBV: HepG2 (95 genomic features); MCPyV: HeLa-S3, SiHa and NHEK
(98 genomic features)). Recursive feature elimination selected the smallest subset of genomic features,
resulting in an RF that performed nearly as well as the best model (Figure 5).
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Figure 5. Predictive genomic features for each DNA tumor virus. Random forest models were 
developed for each virus and window size, using either the background set or the gene constraint set 
as the negative class. Starting from only the genomic features that were considered relevant to each 
virus, feature elimination was used to select the smallest set of features that gave an ROC within 2% 
of the best model using three-fold cross-validation repeated 10 times on the training set. The optimal 
model was then used to classify a held-out test set (75% of data for training, 25% for testing). The 
entire process was repeated 10 times, once for each of the randomly-selected background sets. The 
number of times each feature was selected for inclusion in the optimal model is shown (white: zero, 
black: 10). Only features selected at least five times for at least one window size are shown. (a) Features 
predictive of HPV integration. (b) ChIP-qPCR of two histone marks predictive of HPV integration, 
H3K36me3 and H3K4me3. The cartoon shows the locations of primers designed to tile across an 
approximately ±500-bp window around the two identical HPV-16 integrants at 13q22.1 in SiHa cells. 
The graph shows the mean and standard deviation of two replicates of qPCR, and a representative 
gel of the products is shown at the right. All primer pairs produced bands at the expected sizes, but 
5′-300 showed additional bands (the arrow indicates the expected size). qPCR quantification showed 
high fold enrichment for 5′-300, some of which may be due to non-specific amplification. However, a 
band is clearly present at the expected size (arrow), suggesting the presence of H3K36me3 and 
H3K4me3 near the integration site. Satellite region 2 (SAT2) and total H3 were used as positive 
controls. (c) Features predictive of HPV integration. (d) Features predictive of HPV integration. 
Comparisons using the gene constraint set are indicated with GC. 
For HPV, RFs selected genomic features indicative of transcription (HeLa.S3_T and euchromatin), 
enhancers (HeLa.S3_E) and LINE and SINE elements (Figure 5a). LINEs were negative predictors of 
integration (Figure 4). The histone modification H3K79me2 was predictive at the ±1000-bp window, 
while H3K36me3, H3K4me3 and H4K20me1 were selected at smaller window sizes. Chromatin 
immunoprecipitation of H3K36me3 and H3K4me3 within ±500 bp of the HPV-16 integration sites in 
SiHa cells revealed these marks to be present in this cell line (Figure 5b). Interestingly, cancer gene 
presence in the immediate vicinity of integration was selected by some models based on BG sets (±100 bp, 
five models; ±500 bp, three models), but not when controlling for gene density (GC sets). 
Figure 5. Predictive genomic features for each DNA tumor virus. Random forest models were
developed for each virus and window size, using either the background set or the gene constraint
set as the negative class. Starting from only the genomic features that were considered relevant to
each virus, feature elimination was used to select the smallest set of features that gave an ROC within
2% of the best model using three-fold cross-validation repeated 10 times on the training set. The
optimal model was then used to classify a held-out test set (75% of data for training, 25% for testing).
The entire process was repeated 10 times, once for each of the randomly-selected background sets.
The number of times each feature was selected for inclusion in the optimal model is shown (white:
zero, black: 10). Only features selected at least five times for at least one window size are shown.
(a) Features predictive of HPV integration. (b) C IP-qPCR of two histone marks predictive of HPV
integration, H3K36me3 and H3K4me3. T cartoon shows the locations of primers designed to tile
across an appr ximat ly ˘500-bp window around the two iden ical H V-16 integ ants at 13q22.1
in SiHa cells. The grap shows the mean and stand rd deviation of two replicat s of qPCR, and
a representative gel of the pro ucts is show at he right. All pr mer pairs produced bands at the
expected sizes, but 51-300 showed additional bands (the arrow indi ates the expected size). qPCR
quantification showed high fold enrichment for 51-300, some of w ich may be due to non-specific
amplification. However, a band is clearly present at the expected size (arrow), suggesting the presence
of H3K36me3 and H3K4me3 near the integration site. Satellite region 2 (SAT2) and total H3 were
used as positive controls. (c) Features predictive of HPV integration. (d) Features predictive of HPV
integration. Comparisons using the gene constraint set are indicated with GC.
For HPV, RFs selected genomic features indicative of transcription (HeLa.S3_T and
euchromatin), enhancers (HeLa.S3_E) and LINE and SINE elements (Figure 5a). LINEs were negative
predictors of integration (Figure 4). The histone modification H3K79me2 was predictive at the
˘1000-bp window, while H3K36me3, H3K4me3 and H4K20me1 were selected at smaller window
sizes. Chromatin i munoprecipitation of H3K36me3 an H3K4me3 within ˘500 bp of the HPV-16
integrati n sites in SiHa cells r vealed these marks to be p esent in this cell line (Figure 5b).
Interestingly, cancer gene presence in the immediate vicinity of integration was selected by some
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models based on BG sets (˘100 bp, five models; ˘500 bp, three models), but not when controlling for
gene density (GC sets).
Within ˘100 bp of HBV sites, differences from random sites were not detected (Figure 4), few
genomic features were eliminated and RFs performed poorly (Table S11). For remaining window
sizes, SINE elements were predictive all 10 times with both BG and GC sets (Figure 5c). LINEs
were a negative predictor of integration. DNA transposon repeats and H3K36me3 were consistently
selected. DNA methylation and Pol2 binding genomic features were important within shorter
windows for both HBV and HPV.
Classification performance of RFs on MCPyV integration was poor (Table S11); however, some
genomic features were consistently selected and warrant future investigation (Figure 5d). The
most stable predictor was SINE elements within the shortest window (˘100 bp), with other repeats
frequently selected. Binding of BDP1, a subunit of the TFIIB complex that recruits RNA PolIII, which
transcribes small ncRNAs, including SINE-encoded RNAs [43], was selected frequently at all window
sizes. The largest window size had the most stable predictors.
2.9. HPV and HBV Integrations Differ among Classes
HPV integration events represented several cancer and HPV types. To investigate potential
differences in integration site preferences between subsets, differences in genomic features were
determined by the Mann–Whitney U-test with Bonferroni correction. Ninety-eight genomic features
based on gene presence and repeats sequence elements and genomic features from HeLa, SiHa and
NHEK cells were used (Figure 6).
HPV types 16 and 18 are the most prevalent in cancer. Most genomic features that differed
between HPV-16 and HPV-18 integration sites scored higher at HPV-18 sites (24/31 genomic features).
Open chromatin, histone modifications, CTCF binding and EZH2 were higher at HPV-16 sites for the
˘10-kb window (Figure 6a). Genomic features associated with HPV-18 sites were less sensitive to
window size.
Comparing integrations in cervical tissues and HNCs (Figure 6b), gene presence, gene
expression, DNA methylation, TF binding, chromatin segments and repeats differed significantly and
scored higher near cervical tissue integrations. Euchromatin regions, histone modifications, CTCF
and EZH2 binding were higher near HNC integration events.
Events surrounding spontaneous integration in the W12 cell line were compared to integration
events in established CESC. Clonal expansion of cells bearing integrations conferring a selective
advantage has been observed [10,17,32,33,44,45], so selectively disadvantageous or neutral
integrations could be underrepresented in tumor biopsies. Lacking in vivo selective pressures,
W12 integrations may better represent the integration process than integration sites observed in
cancers (Figure 6c) [46]. Over two-thirds of genomic features were significantly different between
CESC and spontaneous W12 integrations (59/98). Preference for CESC integration near cancer
genes and higher gene expression were detected at all window sizes in cancers compared to W12.
At the largest window size, few genomic features were found more often near W12 integration
loci, including euchromatin-associated DNase hypersensitive regions and epigenetic indicators of
transcriptionally-silent regions: H3K27me3 (HeLa-S3) and EZH2 binding (NHEK). In NHEK cells,
histone marks associated with active transcription (H3K36me3, H3K4me3 and H3K9ac) were detected
at loci that hosted integrations in cancers. Only one repressive mark was detected, H3K9me1,
indicating that these regions are generally open. H3K79me2 and H4K20me1, both associated
with DNA replication and maintenance of genomic stability [47,48], were frequently detected at
cancer integration sites. In HeLa-S3, several TFs were bound near integration loci from cancer
cases (ENCODE data not available for NHEK). However, HeLa-S3 data cannot distinguish whether
gene expression and epigenetic genomic features were present before integration or reflect changes
accumulated during cancer progression.
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Figure 6. Significant differences were detected between types of viral integration sites. (a) Certain 
features in 7/8 categories were significantly different near HPV-18 integrations compared to HPV-16 
(HPV-16 n = 382, HPV-18 n = 133); and (b) integrations in cervical tissue compared to those in head 
and neck cancers (HNC) (cervical n = 431, HNC n = 59). Regardless of window size or whether or not 
the number of genes was controlled for, gene expression, repeats and certain transcription factors 
Figure 6. Significant differences were detected between types of viral integration sites. (a) Certain
features in 7/8 categories were significantly different near HPV-18 integrations compared to HPV-16
(HPV-16 n = 382, HPV-18 n = 133); and (b) integrations in cervical tissue c mpared to those in head and
neck cancers (HNC) (cervical n = 431, HNC n = 59). Regardless of window size or whether or not the
number of genes was controlled for, gene expression, repeats and certain transcription factors differed
significantly between HPV types (a) and tissues (b). (c) Significant differences between cervical
cancer (n = 419) and W12 cell line (n = 28) integration sites. (d) Significant differences between HBV
integration sites in HCC (n = 628) and tumor-adjacent tissues (n = 618). Significance was determined
using a two-sided Mann–Whitney U-test with Bonferroni correction, α < 0.05. Comparisons using the
gene constraint set are indicated with GC.
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Previous studies detected differences between HBV integration sites in non-tumor and tumor
tissues, possibly due to clonal selection and oncogenesis [15,32]. For HBV, 95 genomic features
from sequence elements and HepG2 cells were analyzed. Comparing HBV integrations in HCC
tumor samples and tumor-adjacent tissues, 91 of 95 genomic features were significantly different after
Bonferroni correction, most of which scored higher near tumor integrations (Figure 6d). Exceptions
were detected at the longest range analyzed and included CEBP, CTCF, FOXA2 and MafF binding.
3. Discussion
Integration is critical to the pathogenesis of multiple viruses. In this large-scale study,
277 genomic features were assessed around known DNA tumor virus integration sites. DNA
tumor virus integrants were not associated with consensus sequence motifs, and repeat regions
predicted their integration. Unlike previous studies, comparisons to random chance indicated
that HPV and HBV have no preference for CFSs, although HIV may. While integration hotspots
8q24.1, 15q22, 17q23.1, 19q13 and 11q13 were within CFSs, this meta-analysis did not detect
integration events at higher frequency in CFSs compared to elsewhere in the genome. Integration
occurred near features suggesting viral tropism: GO term enrichment in keratinization for HPV,
sensory perception for MCPyV and cell type-specific genomic features. Viral preference for
transcriptionally-active gene-dense regions and accessible chromatin was confirmed [15,23,24].
Interestingly, epigenetic modifiers were consistently associated with all viral integration events,
and specific integration-associated marks included H3K36me3, H3K4me3, Pol2 binding and DNA
methylation. Of interest, methylated CpGs within fragile zones of oncogenes prone to translocation
events are targeted by the AID enzyme, resulting in double-stranded DNA breaks [49], which could
facilitate an integration event.
Previous studies noted hotspots of HPV integration in 8q24 and 13q22.1 [14,20,26,36]. While
common high-risk HPVs frequently integrate in 8q24, our results suggest HPV-18 has a stronger
preference than HPV-16. Repeats, enhancers, Pol2 binding, open chromatin and histone modifications
(H3K36me3, H3K4me3, H3K79me2 and H4K20me1) predicted HPV integration. These histone
marks indicate DNA damage, replication and maintenance of genomic stability [47,48], suggesting
integration in damage-prone regions even in the absence of evidence of preference for CFSs.
Viral infection has also been tightly associated with initiation of APOBEC enzymatic machinery,
which causes double-strand DNA breaks that may facilitate integration [50]. DNA replication may
provide open regions for viral integration, and disruption of these marks may contribute to the
frequently-observed genomic instability near HPV integration.
The state of genomic features at the time of integration and within a particular cell is uncertain.
The determination of genomic features using extensive genome-wide studies across biopsies was
impractical, and widely studied cell line data provided reasonable models. HeLa, SiHa and NHEK
originate from anogenital epithelium; however, this may differ from oral epithelium present in
HNCs. NHEK approximated the epithelial cell epigenome prior to virus integration. W12 integration
loci should reflect early integration events, while HeLa cells likely reflect accumulated epigenetic
cancer-associated changes post-integration.
Genomic features present near integration loci in HPV+ cancers differed from those near W12
integration loci. Likewise, clear differences were detected between HBV integrations in tumor and
adjacent non-tumor sources. These data support the hypothesis that only some HPV and HBV
integrations lead to functional changes promoting tumorigenesis. Studies of integration in matched
tumor and normal tissues are lacking for HPV, and further investigation is warranted. While
comparisons may be confounded by the abundance of HPV-16+ HNC cases, integrants demonstrated
clear differences in the integration site genomic feature profile of HPV-16 vs. HPV-18 and HNC vs.
cervical tissues. More features were statistically associated with HPV-18 and cervical integrations.
HBV integration sites frequently occurred in cancer-related genes, and integration may
deregulate these genes in HCC. Preferential integration into actively-transcribed genes may reflect
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open chromatin configuration [27], and integration into hTERT, MLL4/KMT2B, CCNE1 and others
have been reported [15,25,27,29,32,37,51,52]. Recent studies detected integration in promoters, exons
and cancer-related genes more frequently in tumor samples than tumor-adjacent tissue [15,27].
However, others concluded there was no difference in integration near cancer-related genes [8]. Like
the former, we detected a preference for HBV integration in gene-dense regions and cancer genes in
HCC. We found no association with HBV integrations in CFSs.
MCPyV, integrated in 70%–80% of Merkel cell carcinomas [9,10], is newly discovered with
few mapped integration loci. Neuroendocrine tumors displayed an interesting association between
MCPyV integration and sensory perception and G-protein-coupled receptor genes. MCPyV
integration occurred preferentially near SINEs and BDP1 binding sties. Identification of additional
MCPyV integration sites is needed for confirmation.
Unlike the tumor viruses, HIV demonstrated a bias for CFSs and sequence motifs. Previous
studies of HIV integration in GM12878 cells covered 1% of the genome [24]. Our analysis covered the
entire genome, confirming that HIV integrates less often in LINEs and more often in metabolism,
cell cycle and mitosis-associated genes [24]. An association between HIV integration sites and
transcriptionally-active epigenetic marks was noted [24]. Our results align with previous studies,
validating our methods.
Determining DNA tumor virus integration site preference aids the understanding of
virus-mediated tumorigenesis. Unlike HIV, for which effective HIV integrase inhibitors exist [34],
viral and human proteins were previously not known to be essential for HPV, HBV or MCPyV
integration. Understanding features that make human genomic loci prone to DNA tumor
virus integration is an important first step to unveil druggable targets to prevent integration in
infected patients.
4. Materials and Methods
4.1. Detection of HPV-16 Integration in Oral Cancer
DIPS-PCR was performed on 5 oral cancer biopsies according to Luft et al. [31]. PCR products
were purified and sequenced. BLAST analysis was performed to determine homology with HPV-16
and the human genome [53]. The study was conducted in accordance with the Declaration of
Helsinki, and the protocol was approved by the Institutional Review Board of the University of North
Carolina at Chapel Hill (IRB# 05-DENT-1263-ORC).
4.2. Catalog of Viral Integration Sites
In addition to the five novel oral cancer HPV integration sites identified by DIPS-PCR, HPV, HBV,
MCPyV and HIV integrations with mapped genomic positions were cataloged from the literature
(references in File S1). For HPV, depending on the methods, study focus and knowledge at the time,
some integration sites were previously reported as “in” or “near” a gene or CFS. For HPV, HBV and
MCPyV, some studies did not report precise genomic locations. Reported sequences were mapped to
the human genome using BLAST [53]. When no sequence was provided, the cytoband that contains
the nearby gene or CFS was taken to be the integration site, termed a broad site. Analyses were
done for the entire set of HPV integration events (n = 589) and for only those with precisely-mapped
locations (n = 92). Viral integration site lengths are provided (Figure S2). HIV integration site
sequences [24] were retrieved from GenBank (EI522403–EI666579) and mapped to hg19 using the
BLAST-like Alignment Tool (BLAT) [54]. Hits were filtering to remove matches that started further
than 3 nucleotides from the HIV LTR, as in the original analysis, resulting in 45,304 HIV integration
sites. Details of integration sites and references are provided (File S1, Table S4). Circos plots were
used to visualize viral integration sites in the human genome [55].
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4.3. Hotspots
Hotspots of viral integration were determined using a method adapted from the z-score
threshold method of Presson et al. [35]. Briefly, the integration sites in each cytoband were counted
(if a site crossed more than cytoband, each was given an equal fractional count) and divided by the
length of the cytoband in Mb before calculating z-scores using R 3.0.2 [56]. Because viral integration
counts were adjusted for cytoband length, integration events falling within a short cytoband could
be considered a hotspot. The threshold was set at the 99.5 percentile (z = 210.31) or 99 percentile
(z = 79.02) of HPV z-scores.
4.4. GO Term Enrichment Analysis
GO biological process terms were associated with human genes using biomaRt 2.22.0 [57,58].
GO terms enriched among the genes found within windows around viral integration sites were
identified using the R package topGO 2.18.0 [59] with all human genes as the background set [59].
Significantly-enriched terms were found using the Fisher exact test with Bonferroni multiple testing
correction (α = 0.05).
4.5. Fragile Sites
The binomial test (binom.test, R 3.0.2 [56]) was used to compare the frequency of integration sites
in CFSs to the fraction of the genome that falls within CFSs. CFSs were defined according to [60].
4.6. Random Sites
Viral integration sites were compared to 10 sets of randomly-selected genomic loci, called
the background (BG) set. For integration sites with inexact mapping, the exact randomly-selected
position was used for determining the background frequency of integration in a CFS and expanded
symmetrically to make a region of the same length as the actual integration site for genomic feature
scoring. For HPV, the Y chromosome was excluded, because no real integration sites were observed
on Y. A second group of background sets was selected for each virus and window size where each
integration site was matched to 10 random loci having a gene presence score (genomic feature scoring,
below) within ˘5% of the actual site’s score. This random set is referred to as the gene constraint
(GC) set.
4.7. Motif Finding
The sequences 10 bp upstream and downstream of viral integration sites or random sites were
retrieved from the human genome using SAMtools 0.1.19 [61]. HOMER v. 4.6 [62] (http://homer.
salk.edu/homer/motif/) was used for de novo motif discovery among the sequences around the
integration sites, with either the sequences around the BG set or the GC set used as the background
sequences. Motifs with a p-value of <1 ˆ 10´10 and present in at least 5% of the target sequences were
considered significant.
4.8. Genomic Feature Scoring
Genomic features were scored within windows of ˘100 bp, ˘500 bp, ˘1 kb and ˘10 kb from
the integration site. Depending on the method used, some integration sites from the literature
were specified as a single nucleotide, while others were reported only as an approximate region.
Integration sites specified as a single nucleotide have the smallest genomic region after the addition of
the surrounding window, defined as the unit region. Feature scores were normalized by the number
of unit regions in the genomic region, after subtracting the length of gaps in the reference assembly.
Two hundred seventy seven genomic features, divided into 8 categories, were scored as
follows: Category 1 consisted of two features, scored as the number of genes present, according to
GENCODE [63], and the number of genes linked to cancer, defined by the COSMIC Cancer Gene
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Census [64]. Category 2, gene expression, was comprised of 5 features. Four were RNA-seq of
HeLa-S3, NHEK, HepG2 and GM12878 from ENCODE [41]. HeLa-S3 are cervical epithelial cells with
HPV-18 integration, and NHEK is an HPV-negative anogenital epithelium. HepG2, a hepatocyte
cell line, was used for liver-tropic HBV. GM12878 is a T-lymphoblastoid cell line previously used
to study HIV integration site selection [24]. Additionally, we performed RNA-seq on SiHa cells,
using Illumina Hi-Seq 2000 with 100-bp single-end reads. All RNA-seq data were processed in the
same way, by mapping to hg19 using TopHat v. 2.0.9 and calculating RPKM with CuffLinks v. 2.1.1.
Replicates were averaged. The expression levels of genes in the window was summed. SiHa RNA-seq
data are available at GEO (GSE67115). Category 3 pertains to open chromatin regions and consists
of 8 features from ENCODE, DNase-seq and FAIRE-seq on HeLa-S3, NHEK, HepG2 and GM12878.
Category 4 included 44 histone modifications measured by ENCODE using ChIP-seq in the four cell
lines. Category 5 was methyl-RRBS data from ENCODE, measuring the percent DNA methylation
in each window for the four cell lines. Category 6 includes 178 features for TF and protein binding
from ENCODE data on HeLa-S3, NHEK, HepG2 and GM12878 cells. Scores for Categories 3, 4 and
6 were the counts of peaks that fall completely within the windows. Category 7 was the 7 chromatin
segmentation states determined by Hoffman et al. using ChromHMM and Segway on HeLa-S3,
HepG2 and GM12878 [65]. These seven states are based on histone modifications, Pol2, CTCF and
open chromatin and include transcription start site (TSS), promoter flanking (PF), enhancer (E), weak
enhancer (WE), CTCF binding (CTCF), transcribed region (T) and repressed or inactive region (R) [65].
As stated above, all feature scores were normalized for the length of the region. A full list of features
and associated data sources is given in Table S10.
4.9. Statistical Analysis
To determine whether genomic features detected around loci differ between HPV types, cancer
types, cancer vs. normal samples or actual integrations sites vs. random sites, the Mann–Whitney
U-test was performed. The Bonferroni method was used to correct for multiple testing, with α = 0.05.
The results were visualized in a heatmap, using the heatmap.2 function in the gplots 2.16.0 R
package [66], without clustering.
4.10. Selection of Features to Classify Integration and Random Sites
RF models were developed for each virus and window size, using either the BG set or GC set as
the negative class. For each of the 10 sets of each negative class, the data were split into a held-out
testing set (25%) and a training set (75%). Using three-fold cross-validation repeated 10 times, feature
elimination was used to select the smallest set of features that gave an ROC within 2% of the best
model using the R package caret 6.0–30 and rfe function [67]. For each fold, the features were selected
using 2/3 of the training data, and the remaining 1/3 was used to calculate ROC. The number of
times (max = 10) each genomic feature was selected for inclusion in the final model using each
random set was counted. The optimal model was then used to classify the remaining 25% of the data
that was held-out of the entire feature selection and training process (testing set), and the accuracy,
sensitivity and specificity of classification of the test set were averaged over the 10 RFs (Table S11).
Genomic features that were selected in most RFs (Figure 5) and all selected genomic features are
shown (Figure S7). The features selected for each RF were visualized using the heatmap.2 function in
the gplots 2.16.0 R package [66], without clustering.
4.11. Cell Culture
SiHa cells (ATCC HTB-35) were grown in 5% CO2 in High Glucose Dulbecco’s Modified Eagle
Medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco).
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4.12. Chromatin Immunoprecipitation Assay
SiHa cells were seeded (5 ˆ 106 cells) on 15-cm dishes. At 90% confluence, cells were treated with
37% formaldehyde (Sigma) added to a final concentration of 1% and incubated for 10 min. Glycine
was added to cells at 10ˆ for 5 min to quench crosslinking. Both fixation and quenching steps were
performed at room temperature and with constant rotation in a fume hood. Chromatin preparation:
nuclei preparation, chromatin shearing and subsequent immunoprecipitations were performed using
the Simple ChIP Plus Enzymatic Chromatin IP Kit (Cell Signaling Technology, Danvers, MA, USA)
with the following modifications. Chromatin was enzymatically digested by the addition of 2 µL
micrococcal nuclease and incubation at 37 ˝C for 15 min. Chromatin digest was stopped by the
addition of 40 µL of 0.5 M EDTA. DNA concentration was obtained from 25-µL samples, and equal
amounts of chromatin were added to each immunoprecipitation (IP) based on these calculations.
Immunoprecipitation: 2% of the chromatin from each treatment condition was stored as the input
control. Four micrograms of chromatin per IP were used. Lysates were pre-cleared for 1 h with
rotation using protein-G magnetic beads (Cell Signaling Technology), then incubated overnight at
4 ˝C with either: (1) anti-histone H3 lysine 4 tri-methyl (H3K4me3) (EpiCypher Inc., Chapel Hill,
NC, USA) at a concentration of 2 µL/IP; (2) anti-histone H3 lysine 36 tri-methyl (H3K36me3) at
a concentration of 2 µL/IP (Cell Signaling Technology); (3) anti-histone H3 XP (Cell Signaling
Technology) at 10 µL/IP; or (4) normal rabbit IgG (negative control) (Cell Signaling Technology) at
1 µL/IP of chromatin. Ten microliters of protein-G magnetic beads were added to each IP, and the
incubation was continued for 2 h at 4 ˝C. Bead-chromatin complexes were washed and eluted, and
cross-linking was reversed using 5 M NaCl and proteinase K. DNA was purified using either the
provided purification spin columns or the ChIP DNA Clean & Concentrator kit (Zymo Research).
Precipitated DNA was diluted 1:2 in dH2O and used for real-time qPCR.
4.13. Chromatin Immunoprecipitation Quantification via qPCR
Real-time qPCR was performed using the Roche Lightcycler 480 (Roche Diagnostics,
Indianapolis, IN, USA) using the following protocol: 95 ˝C for 10 min, followed by 45 cycles of 95 ˝C
for 15 s, 60 ˝C (or 53 ˝C) for 1 min followed by signal acquisition. PCR reactions were assembled in
a PCR hood using 1ˆ SYBR Green PCR Master Mix (Roche Diagnostics), 300 nM primers and 2 µL of
diluted template for a total reaction volume of 10 µL. Primers were chosen to approximate a ˘500-bp
window around the two HPV-16 integration sites at 13q22.1 in SiHa cells. The two integrated copies
have identical breakpoints and are separated by a duplicated segment of the human genome [18].
Primer sets covering two regions failed to produce an amplification product: the region from the 31
junction to approximately 400 bp 31 and approximately 300–500 bp 51 of the 51 junction, so histone
marks in these sections of the window were not observed. Primer sequences are given in Table S12.
To confirm qPCR signal and amplification, the qPCR reactions were diluted 1:2 and run on a 3%
TBE-agarose gel stained with 0.05 µg/mL ethidium bromide. Fold enrichment was determined as
follows: input dilution factor (2%) = log2(50) = 5.64; ∆Ct input normalized IP value = (Ct[IP] ´
Ct[input ˆ 5.64]); IgG adjusted IP Ct value (∆∆Ct) = (∆Ct[IP] ´ ∆Ct[IgG]); fold enrichment above
IgG = 2p´∆∆Ctq.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/
2072-6694/7/4/0887/s1. File S1. Supplemental references, tables and figures. Contains Tables S1–S3, S5, S6,
S8, S11, and S12 and Figures S1–S7. Table S4: Viral integration sites characterized in this study. Source: reference
for integration site; cellType: cell or tissue in which integration site was found; chrBand: cytoband in which
the integration site falls; Coordinates: genomic locus of integration; FusionTranscript: whether a viral-human
fusion transcript was detected; Sample Name: sample id used in the original study; Accession: identifier for
nearest reported gene to integration site; CoorMethod: method used to determine the integration coordinates;
ExpMethod: method used to determine the integration site in the original study; NuclAssayed: type of nucleic
acid assayed by the experimental method. Table S7: GO terms that were significantly enriched within the
windows around viral integration sites. Table S9: Motifs enriched at HIV integration sites compared to the
random loci (BG or GC sets). Table S10: Details of data sources for each genomic feature.
2231
Cancers 2015, 7, 2217–2235
Acknowledgments: We are grateful to Shawn Gomez for scientific guidance, and comments from
Sylvia Frazier-Bowers helped to greatly improve an earlier version of the manuscript. The results published
here are based on data from the ENCODE Consortium (Table S10). Some of the genomic features used in this
research were derived from a HeLa cell line. Henrietta Lacks, and the HeLa cell line that was established from her
tumor cells without her knowledge or consent in 1951, have made significant contributions to scientific progress
and advances in human health. We are grateful to Henrietta Lacks, now deceased, and to her surviving family
members for their contributions to biomedical research. We would also like to acknowledge financial support
from NIH/NIDCR T90DE021986 and NIDCR 1 R56 DE023940-01.
Author Contributions: DIPS-PCR for HPV integration sites was conducted by W.T.S. The literature search for
viral integration sites, RNA-seq analysis, feature scoring and statistics were performed by J.D.-H. ChIP-qPCR
was performed by D.L.C.G. Writing and revisions were done by J.D.-H. and J.W.-C. The project was coordinated
by J.W.-C.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Berry, C.; Hannenhalli, S.; Leipzig, J.; Bushman, F.D. Selection of target sites for mobile DNA integration in
the human genome. PLoS Comput. Biol. 2006, 2, e157. [CrossRef] [PubMed]
2. De Jong, J.; Akhtar, W.; Badhai, J.; Rust, A.G.; Rad, R.; Hilkens, J.; Berns, A.; van Lohuizen, M.;
Wessels, L.F.A.; de Ridder, J. Chromatin landscapes of retroviral and transposon integration profiles.
PLoS Genet. 2014, 10, e1004250. [CrossRef] [PubMed]
3. Kim, S.; Kim, N.; Dong, B.; Boren, D.; Lee, S.A.; Das Gupta, J.; Gaughan, C.; Klein, E.A.; Lee, C.;
Silverman, R.H.; et al. Integration site preference of xenotropic murine leukemia virus-related virus, a new
human retrovirus associated with prostate cancer. J. Virol. 2008, 82, 9964–9977. [CrossRef] [PubMed]
4. Brady, T.; Agosto, L.; Malani, N. HIV integration site distributions in resting and activated CD4+ T cells
infected in culture. AIDS 2009, 23, 1461–1471. [CrossRef] [PubMed]
5. De Martel, C.; Ferlay, J.; Franceschi, S.; Vignat, J.; Bray, F.; Forman, D.; Plummer, M. Global burden of
cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol. 2012, 13, 607–615.
[PubMed]
6. Chaturvedi, A.K.; Engels, E.A.; Pfeiffer, R.M.; Hernandez, B.Y.; Xiao, W.; Kim, E.; Jiang, B.; Goodman, M.T.;
Sibug-Saber, M.; Cozen, W.; et al. Human papillomavirus and rising oropharyngeal cancer incidence in the
United States. J. Clin. Oncol. 2011, 29, 4294–4301. [CrossRef] [PubMed]
7. Feitelson, M.A.; Lee, J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett.
2007, 252, 157–170. [CrossRef] [PubMed]
8. Jiang, S.; Yang, Z.; Li, W.; Li, X.; Wang, Y.; Zhang, J.; Xu, C.; Chen, P.-J.; Hou, J.; McCrae, M.A.; et al.
Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesis.
PLoS ONE 2012, 7, e40363. [CrossRef] [PubMed]
9. Martel-Jantin, C.; Filippone, C.; Cassar, O.; Peter, M.; Tomasic, G.; Vielh, P.; Brière, J.; Petrella, T.;
Aubriot-Lorton, M.H.; Mortier, L.; et al. Genetic variability and integration of Merkel cell polyomavirus
in Merkel cell carcinoma. Virology 2012, 426, 134–142. [CrossRef] [PubMed]
10. Feng, H.; Shuda, M.; Chang, Y.; Moore, P. Clonal integration of a polyomavirus in human Merkel cell
carcinoma. Science 2008, 319, 1096–1100. [CrossRef] [PubMed]
11. Jeon, S.; Lambert, P.F. Integration of human papillomavirus type 16 DNA into the human genome leads to
increased stability of E6 and E7 mRNAs: Implications for cervical carcinogenesis. Proc. Natl. Acad. Sci. USA
1995, 92, 1654–1658. [CrossRef] [PubMed]
12. Tu, H.; Bonura, C.; Giannini, C.; Mouly, H.; Soussan, P.; Kew, M.; Paterlini-Brechot, P.; Brechot, C.;
Kremsdorf, D. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in
hepatocellular carcinoma tissues. Cancer Res. 2001, 61, 7803–7810. [PubMed]
13. Shuda, M.; Feng, H.; Kwun, H.J.; Rosen, S.T.; Gjoerup, O.; Moore, P.S.; Chang, Y. T antigen mutations are
a human tumor-specific signature for Merkel cell polyomavirus. Proc. Natl. Acad. Sci. USA 2008, 105,
16272–16277. [CrossRef] [PubMed]
14. Peter, M.; Rosty, C.; Couturier, J.; Radvanyi, F.; Teshima, H.; Sastre-Garau, X. MYC activation associated
with the integration of HPV DNA at the MYC locus in genital tumors. Oncogene 2006, 25, 5985–5993.
[CrossRef] [PubMed]
2232
Cancers 2015, 7, 2217–2235
15. Sung, W.-K.; Zheng, H.; Li, S.; Chen, R.; Liu, X.; Li, Y.; Lee, N.P.; Lee, W.H.; Ariyaratne, P.N.; Tennakoon, C.;
et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 2012, 44,
765–769. [CrossRef] [PubMed]
16. Lau, C.-C.; Sun, T.; Ching, A.K.K.; He, M.; Li, J.-W.; Wong, A.M.; Co, N.N.; Chan, A.W.H.; Li, P.-S.;
Lung, R.W.M.; et al. Viral-human chimeric transcript predisposes risk to liver cancer development and
progression. Cancer Cell 2014, 25, 335–349. [CrossRef] [PubMed]
17. Lace, M.J.; Anson, J.R.; Klussmann, J.P.; Wang, D.H.; Smith, E.M.; Haugen, T.H.; Turek, L.P.
Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in
HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those
found in cervical cancers. J. Virol. 2011, 85, 1645–1654. [CrossRef] [PubMed]
18. Akagi, K.; Li, J.; Broutian, T.R.; Padilla-Nash, H.; Xiao, W.; Jiang, B.; Rocco, J.W.; Teknos, T.N.; Kumar, B.;
Wangsa, D.; et al. Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal
genomic instability. Genome Res. 2014, 24, 185–199. [CrossRef] [PubMed]
19. Thorland, E.C.; Myers, S.L.; Gostout, B.S.; Smith, D.I. Common fragile sites are preferential targets for
HPV16 integrations in cervical tumors. Oncogene 2003, 22, 1225–1237. [CrossRef]
20. Ferber, M.J.; Thorland, E.C.; Brink, A.A.; Rapp, A.K.; Phillips, L.A.; McGovern, R.; Gostout, B.S.;
Cheung, T.H.; Chung, T.K.; Fu, W.Y.; et al. Preferential integration of human papillomavirus type 18 near
the c-myc locus in cervical carcinoma. Oncogene 2003, 22, 7233–7242. [CrossRef] [PubMed]
21. Wentzensen, N.; Vinokurova, S.; von Knebel Doeberitz, M. Systematic review of genomic integration sites
of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital
tract. Cancer Res. 2004, 64, 3878–3884. [CrossRef] [PubMed]
22. Wilke, C.M.; Hall, B.K.; Hoge, A.; Paradee, W.; Smith, D.I.; Glover, T.W. FRA3B extends over a broad region
and contains a spontaneous HPV16 integration site: Direct evidence for the coincidence of viral integration
sites and fragile sites. Hum. Mol. Genet. 1996, 5, 187–195. [CrossRef]
23. Klimov, E.; Vinokourova, S.; Moisjak, E.; Rakhmanaliev, E.; Kobseva, V.; Laimins, L.; Kisseljov, F.;
Sulimova, G. Human papilloma viruses and cervical tumours: Mapping of integration sites and analysis of
adjacent cellular sequences. BMC Cancer 2002, 2, 24. [CrossRef] [PubMed]
24. Wang, G.P.; Ciuffi, A.; Leipzig, J.; Berry, C.C.; Bushman, F.D. HIV integration site selection: Analysis by
massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 2007, 17,
1186–1194. [CrossRef] [PubMed]
25. Ferber, M.J.; Montoya, D.P.; Yu, C.; Aderca, I.; McGee, A.; Thorland, E.C.; Nagorney, D.M.; Gostout, B.S.;
Burgart, L.J.; Boix, L.; et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV)
into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene
2003, 22, 3813–3820. [CrossRef] [PubMed]
26. Couturier, J.; Sastre-Garau, X.; Schneider-Maunoury, S.; Labib, A.; Orth, G. Integration of papillomavirus
DNA near myc genes in genital carcinomas and its consequences for proto-oncogene expression. J. Virol.
1991, 65, 4534–4538. [PubMed]
27. Li, X.; Zhang, J.; Yang, Z.; Kang, J.; Jiang, S.; Zhang, T.; Chen, T.; Li, M.; Lv, Q.; Chen, X.; et al. The function of
targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma. J. Hepatol.
2014, 60, 975–984. [CrossRef] [PubMed]
28. Wagner, T.A.; McLaughlin, S.; Garg, K.; Cheung, C.Y.K.; Larsen, B.B.; Styrchak, S.; Huang, H.C.;
Edlefsen, P.T.; Mullins, J.I.; Frenkel, L.M. Proliferation of cells with HIV integrated into cancer genes
contributes to persistent infection. Science 2014, 345, 570–573. [CrossRef] [PubMed]
29. Paterlini-Bréchot, P.; Saigo, K.; Murakami, Y.; Chami, M.; Gozuacik, D.; Mugnier, C.; Lagorce, D.; Bréchot, C.
Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently
targets human telomerase gene. Oncogene 2003, 22, 3911–3916. [CrossRef] [PubMed]
30. Ziegert, C.; Wentzensen, N.; Vinokurova, S.; Kisseljov, F.; Einenkel, J.; Hoeckel, M.; von Knebel
Doeberitz, M. A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript
and genome-based amplification techniques. Oncogene 2003, 22, 3977–3984. [CrossRef] [PubMed]
31. Luft, F.; Klaes, R.; Nees, M.; Dürst, M.; Heilmann, V.; Melsheimer, P.; von Knebel Doeberitz, M.
Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular
characterization in cervical cancer cells. Int. J. Cancer 2001, 92, 9–17. [CrossRef]
2233
Cancers 2015, 7, 2217–2235
32. Ding, D.; Lou, X.; Hua, D.; Yu, W.; Li, L.; Wang, J.; Gao, F.; Zhao, N.; Ren, G.; Li, L.; et al. Recurrent targeted
genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based
approach. PLoS Genet. 2012, 8, e1003065. [CrossRef] [PubMed]
33. Schmitz, M.; Driesch, C.; Jansen, L.; Runnebaum, I.B.; Dürst, M. Non-random integration of the HPV
genome in cervical cancer. PLoS ONE 2012, 7, e39632. [CrossRef] [PubMed]
34. Vandegraaff, N.; Engelman, A. Molecular mechanisms of HIV integration and therapeutic intervention.
Expert Rev. Mol. Med. 2007, 9, 1–19. [CrossRef] [PubMed]
35. Presson, A.P.; Kim, N.; Xiaofei, Y.; Chen, I.S.; Kim, S. Methodology and software to detect viral integration
site hot-spots. BMC Bioinform. 2011, 12, 367. [CrossRef] [PubMed]
36. Kraus, I.; Driesch, C.; Vinokurova, S.; Hovig, E.; Schneider, A.; von Knebel Doeberitz, M.; Dürst, M. The
majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences of known
or predicted genes. Cancer Res. 2008, 68, 2514–2522. [CrossRef] [PubMed]
37. Saigo, K.; Yoshida, K.; Ikeda, R.; Sakamoto, Y.; Murakami, Y.; Urashima, T.; Asano, T.; Kenmochi, T.;
Inoue, I. Integration of hepatitis B virus DNA into the myeloid/lymphoid or mixed-lineage leukemia
(MLL4) gene and rearrangements of MLL4 in human hepatocellular carcinoma. Hum. Mutat. 2008, 29,
703–708. [CrossRef] [PubMed]
38. Wu, X.; Li, Y.; Crise, B.; Burgess, S.M.; Munroe, D.J. Weak palindromic consensus sequences are a common
feature found at the integration target sites of many retroviruses. J. Virol. 2005, 79, 5211–5214. [CrossRef]
[PubMed]
39. Holman, A.G.; Coffin, J.M. Symmetrical base preferences surrounding HIV-1, avian sarcoma/leukosis
virus, and murine leukemia virus integration sites. Proc. Natl. Acad. Sci. USA 2005, 102, 6103–6107.
[CrossRef] [PubMed]
40. Wentzensen, N.; Ridder, R.; Klaes, R. Characterization of viral-cellular fusion transcripts in a large series of
HPV16 and 18 positive anogenital lesions. Oncogene 2002, 21, 419–426. [CrossRef] [PubMed]
41. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature
2012, 489, 57–74.
42. Shimazaki, N.; Lieber, M.R. Histone methylation and V(D)J recombination. Int. J. Hematol. 2014, 100,
230–237. [CrossRef] [PubMed]
43. Dieci, G.; Fiorino, G.; Castelnuovo, M.; Teichmann, M.; Pagano, A. The expanding RNA polymerase III
transcriptome. Trends Genet. 2007, 23, 614–622. [CrossRef] [PubMed]
44. Jiang, Z.; Jhunjhunwala, S.; Liu, J.; Haverty, P.M.; Kennemer, M.I.; Guan, Y.; Lee, W.; Carnevali, P.; Stinson, J.;
Johnson, S.; et al. The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma
patients. Genome Res. 2012, 22, 593–601. [CrossRef] [PubMed]
45. Maldarelli, F.; Wu, X.; Su, L.; Simonetti, F.R.; Shao, W.; Hill, S.; Spindler, J.; Ferris, A.L.; Mellors, J.W.;
Kearney, M.F.; et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected
cells. Science 2014, 345, 179–183. [CrossRef] [PubMed]
46. Dall, K.L.; Scarpini, C.G.; Roberts, I.; Winder, D.M.; Stanley, M.A.; Muralidhar, B.; Herdman, M.T.;
Pett, M.R.; Coleman, N. Characterization of naturally occurring HPV16 integration sites isolated from
cervical keratinocytes under noncompetitive conditions. Cancer Res. 2008, 68, 8249–8259. [CrossRef]
[PubMed]
47. Fu, H.; Maunakea, A.K.; Martin, M.M.; Huang, L.; Zhang, Y.; Ryan, M.; Kim, R.; Lin, C.M.; Zhao, K.;
Aladjem, M.I. Methylation of histone H3 on lysine 79 associates with a group of replication origins and
helps limit DNA replication once per cell cycle. PLoS Genet. 2013, 9, e1003542. [CrossRef] [PubMed]
48. Beck, D.B.; Oda, H.; Shen, S.S.; Reinberg, D. PR-Set7 and H4K20me1: At the crossroads of genome integrity,
cell cycle, chromosome condensation, and transcription. Genes Dev. 2012, 26, 325–337. [CrossRef] [PubMed]
49. Cui, X.; Lu, Z.; Kurosawa, A.; Klemm, L.; Bagshaw, A.T.; Tsai, A.G.; Gemmell, N.; Müschen, M.; Adachi, N.;
Hsieh, C.-L.; et al. Both CpG methylation and activation-induced deaminase are required for the fragility
of the human bcl-2 major breakpoint region: Implications for the timing of the breaks in the t(14;18)
translocation. Mol. Cell. Biol. 2013, 33, 947–957. [CrossRef] [PubMed]
50. Franchini, D.-M.; Petersen-Mahrt, S.K. AID and APOBEC deaminases: Balancing DNA damage in
epigenetics and immunity. Epigenomics 2014, 6, 427–443. [CrossRef] [PubMed]
2234
Cancers 2015, 7, 2217–2235
51. Murakami, Y.; Saigo, K.; Takashima, H.; Minami, M.; Okanoue, T.; Bréchot, C.; Paterlini-Bréchot, P. Large
scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut
2005, 54, 1162–1168. [CrossRef] [PubMed]
52. Bonilla Guerrero, R.; Roberts, L.R. The role of hepatitis B virus integrations in the pathogenesis of human
hepatocellular carcinoma. J. Hepatol. 2005, 42, 760–777. [CrossRef] [PubMed]
53. Altschul, S.F.; Gish, W.; Miller, W.; Myers, E.W.; Lipman, D.J. Basic local alignment search tool. J. Mol. Biol.
1990, 215, 403–410. [CrossRef]
54. Kent, W.J. BLAT—The BLAST-Like Alignment Tool. Genome Res. 2002, 12, 656–664. [CrossRef] [PubMed]
55. Krzywinski, M.; Schein, J.; Birol, I.; Connors, J.; Gascoyne, R.; Horsman, D.; Jones, S.J.; Marra, M.A. Circos:
An information aesthetic for comparative genomics. Genome Res. 2009, 19, 1639–1645. [CrossRef] [PubMed]
56. R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical
Computing: Vienna, Austria, 2014.
57. Durinck, S.; Moreau, Y.; Kasprzyk, A.; Davis, S.; de Moor, B.; Brazma, A.; Huber, W. BioMart and
Bioconductor: A powerful link between biological databases and microarray data analysis. Bioinformatics
2005, 21, 3439–3440. [CrossRef] [PubMed]
58. Durinck, S.; Spellman, P.T.; Birney, E.; Huber, W. Mapping identifiers for the integration of genomic datasets
with the R/Bioconductor package biomaRt. Nat. Protoc. 2009, 4, 1184–1191. [CrossRef] [PubMed]
59. Alexa, A.; Rahnenfuhrer, J. topGO: Enrichment analysis for Gene Ontology, R package version 2.14.0; 2010.
60. Lukusa, T.; Fryns, J.P. Human chromosome fragility. Biochim. Biophys. Acta 2008, 1779, 3–16. [CrossRef]
[PubMed]
61. Li, H.; Handsaker, B.; Wysoker, A.; Fennell, T.; Ruan, J.; Homer, N.; Marth, G.; Abecasis, G.; Durbin, R. The
Sequence Alignment/Map format and SAMtools. Bioinformatics 2009, 25, 2078–2079. [CrossRef] [PubMed]
62. Heinz, S.; Benner, C.; Spann, N.; Bertolino, E.; Lin, Y.C.; Laslo, P.; Cheng, J.X.; Murre, C.; Singh, H.;
Glass, C.K. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements
required for macrophage and B cell identities. Mol. Cell 2010, 38, 576–589. [CrossRef] [PubMed]
63. Harrow, J.; Frankish, A.; Gonzalez, J.M.; Tapanari, E.; Diekhans, M.; Kokocinski, F.; Aken, B.L.; Barrell, D.;
Zadissa, A.; Searle, S.; et al. GENCODE: The reference human genome annotation for The ENCODE Project.
Genome Res. 2012, 22, 1760–1774. [CrossRef] [PubMed]
64. Futreal, P.A.; Coin, L.; Marshall, M.; Down, T.; Hubbard, T.; Wooster, R.; Rahman, N.; Stratton, M.R.
A census of human cancer genes. Nat. Rev. Cancer 2004, 4, 177–183. [CrossRef] [PubMed]
65. Hoffman, M.M.; Ernst, J.; Wilder, S.P.; Kundaje, A.; Harris, R.S.; Libbrecht, M.; Giardine, B.;
Ellenbogen, P.M.; Bilmes, J.A.; Birney, E.; et al. Integrative annotation of chromatin elements from ENCODE
data. Nucleic Acids Res. 2013, 41, 827–841. [CrossRef] [PubMed]
66. Warnes, G.R.; Bolker, B.; Bonebakker, L.; Gentleman, R.; Liaw, W.H.A.; Lumley, T.; Maechler, M.;
Magnusson, A.; Moeller, S.; Schwartz, M.; et al. gplots: Various R Programming Tools for Plotting Data.
2015, R package version 2.6.0.
67. Kuhn, M.; Wing, J.; Weston, S.; Williams, A.; Keefer, C.; Engelhardt, A.; Cooper, T.; Mayer, Z.; the R Core
Team. caret: Classification and Regression Training. Astrophysics Source Code Library 2014, R package
version 6.0-30.
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open
access article distributed under the terms and conditions of the Creative Commons by
Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
2235
